Skip to main content
Top
Published in: BMC Infectious Diseases 1/2010

Open Access 01-12-2010 | Research article

Modelling imperfect adherence to HIV induction therapy

Authors: Rachelle E Miron, Robert J Smith

Published in: BMC Infectious Diseases | Issue 1/2010

Login to get access

Abstract

Background

Induction-maintenance therapy is a treatment regime where patients are prescribed an intense course of treatment for a short period of time (the induction phase), followed by a simplified long-term regimen (maintenance). Since induction therapy has a significantly higher chance of pill fatigue than maintenance therapy, patients might take drug holidays during this period. Without guidance, patients who choose to stop therapy will each be making individual decisions, with no scientific basis.

Methods

We use mathematical modelling to investigate the effect of imperfect adherence during the inductive phase. We address the following research questions: 1. Can we theoretically determine the maximal length of a possible drug holiday and the minimal number of doses that must subsequently be taken while still avoiding resistance? 2. How many drug holidays can be taken during the induction phase?

Results

For a 180 day therapeutic program, a patient can take several drug holidays, but then has to follow each drug holiday with a strict, but fairly straightforward, drug-taking regimen. Since the results are dependent upon the drug regimen, we calculated the length and number of drug holidays for all fifteen protease-sparing triple-drug cocktails that have been approved by the US Food and Drug Administration.

Conclusions

Induction therapy with partial adherence is tolerable, but the outcome depends on the drug cocktail. Our theoretical predictions are in line with recent results from pilot studies of short-cycle treatment interruption strategies and may be useful in guiding the design of future clinical trials.
Appendix
Available only for authorised users
Literature
1.
go back to reference Steinbrook R: The AIDS Epidemic - A Progress Report from Mexico City. N Engl J Med. 2008, 359: 885-887. 10.1056/NEJMp0805761.CrossRefPubMed Steinbrook R: The AIDS Epidemic - A Progress Report from Mexico City. N Engl J Med. 2008, 359: 885-887. 10.1056/NEJMp0805761.CrossRefPubMed
2.
go back to reference McCune J: The dynamics of CD4+T-cell depletion in HIV disease. Nature. 2001, 410: 974-979. 10.1038/35073648.CrossRefPubMed McCune J: The dynamics of CD4+T-cell depletion in HIV disease. Nature. 2001, 410: 974-979. 10.1038/35073648.CrossRefPubMed
3.
go back to reference Yeni PG, Hammer SM, Hirsch M, Saag M, Schechter M, Carpenter CCJ, Fischi MA, Gatell JM, Gazzard BG, Jacobsen D, Katzenstein DA, Montaner JSG, Richman DD, Schooley RT, Thompson MA, Vella S, Volberding PA: Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society - USA Panel. JAMA. 2004, 292: 251-265. 10.1001/jama.292.2.251.CrossRefPubMed Yeni PG, Hammer SM, Hirsch M, Saag M, Schechter M, Carpenter CCJ, Fischi MA, Gatell JM, Gazzard BG, Jacobsen D, Katzenstein DA, Montaner JSG, Richman DD, Schooley RT, Thompson MA, Vella S, Volberding PA: Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society - USA Panel. JAMA. 2004, 292: 251-265. 10.1001/jama.292.2.251.CrossRefPubMed
4.
go back to reference Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ, Ruiz NM: Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 1999, 341: 1865-1873. 10.1056/NEJM199912163412501.CrossRefPubMed Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ, Ruiz NM: Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 1999, 341: 1865-1873. 10.1056/NEJM199912163412501.CrossRefPubMed
5.
go back to reference Moyle G: Protease inhibitor-sparing regimens: new evidence strengthens position. J Acq Immun Def Synd. 2003, 33 (Suppl 1): 17-25. Moyle G: Protease inhibitor-sparing regimens: new evidence strengthens position. J Acq Immun Def Synd. 2003, 33 (Suppl 1): 17-25.
6.
go back to reference Atlice FL, Friedland GH: The era of adherence to HIV therapy. Ann Intern Med. 1998, 129: 503-505.CrossRef Atlice FL, Friedland GH: The era of adherence to HIV therapy. Ann Intern Med. 1998, 129: 503-505.CrossRef
8.
go back to reference Philips AN, Youle M, Johnson M, Loveday C: Use of stochastic model to develop understanding of the impact of different patterns of antiretroviral drug use on resistance development. AIDS. 2001, 15: 2211-2220. 10.1097/00002030-200111230-00001.CrossRef Philips AN, Youle M, Johnson M, Loveday C: Use of stochastic model to develop understanding of the impact of different patterns of antiretroviral drug use on resistance development. AIDS. 2001, 15: 2211-2220. 10.1097/00002030-200111230-00001.CrossRef
9.
go back to reference Tchetgen E, Kaplan EH, Friedland GH: Public health consequences of screening patients for adherence to highly active antiretroviral therapy. J AIDS. 2001, 26: 118-129. Tchetgen E, Kaplan EH, Friedland GH: Public health consequences of screening patients for adherence to highly active antiretroviral therapy. J AIDS. 2001, 26: 118-129.
10.
go back to reference Huang Y, Rosenkranz S, Wu H: Modeling HIV dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivity. Math Biosci. 2003, 184: 165-186. 10.1016/S0025-5564(03)00058-0.CrossRefPubMed Huang Y, Rosenkranz S, Wu H: Modeling HIV dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivity. Math Biosci. 2003, 184: 165-186. 10.1016/S0025-5564(03)00058-0.CrossRefPubMed
11.
go back to reference Huang Y, Liu D, H W: Hierarchical Bayesian methods for estimation of parameters in longitudinal HIV dynamic system. Biometrics. 2004, 62: 413-423. 10.1111/j.1541-0420.2005.00447.x.CrossRef Huang Y, Liu D, H W: Hierarchical Bayesian methods for estimation of parameters in longitudinal HIV dynamic system. Biometrics. 2004, 62: 413-423. 10.1111/j.1541-0420.2005.00447.x.CrossRef
12.
go back to reference Ferguson NM, Donnelly CA, Hooper J, Ghani AC, Fraser C, Bartley L: Adherence to antiretroviral therapy and its impact on clinical outcome in HIV-infected patients. J R Soc Interface. 2005, 2: 349-363. 10.1098/rsif.2005.0037.CrossRefPubMedPubMedCentral Ferguson NM, Donnelly CA, Hooper J, Ghani AC, Fraser C, Bartley L: Adherence to antiretroviral therapy and its impact on clinical outcome in HIV-infected patients. J R Soc Interface. 2005, 2: 349-363. 10.1098/rsif.2005.0037.CrossRefPubMedPubMedCentral
13.
go back to reference Smith RJ: Adherence to antiretroviral HIV drugs: how many doses can you miss before resistance emerges?. Proc R Soc B. 2006, 273: 617-624. 10.1098/rspb.2005.3352.CrossRefPubMed Smith RJ: Adherence to antiretroviral HIV drugs: how many doses can you miss before resistance emerges?. Proc R Soc B. 2006, 273: 617-624. 10.1098/rspb.2005.3352.CrossRefPubMed
14.
go back to reference Krakovska O, Wahl LM: Optimal drug treatment regimens for HIV depend on adherence. J Theor Biol. 2007, 246: 499-509. 10.1016/j.jtbi.2006.12.038.CrossRefPubMed Krakovska O, Wahl LM: Optimal drug treatment regimens for HIV depend on adherence. J Theor Biol. 2007, 246: 499-509. 10.1016/j.jtbi.2006.12.038.CrossRefPubMed
15.
go back to reference Friedland GH, Williams A: Attaining higher goals in HIV treatment: the central importance of adherence. AIDS. 1999, 13 (Suppl 1): 61-72. Friedland GH, Williams A: Attaining higher goals in HIV treatment: the central importance of adherence. AIDS. 1999, 13 (Suppl 1): 61-72.
16.
go back to reference Reijers MH, Weverling GJ, Jurriaans S, Wit FW, Weigel HM, Ten Kate RW, Mulder JW, Frissen PH, van Leeuwen R, Reiss P, Schuitemaker H, de Wolf F, Lange JM: Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication study. Lancet. 1998, 352: 185-190. 10.1016/S0140-6736(98)06193-5.CrossRefPubMed Reijers MH, Weverling GJ, Jurriaans S, Wit FW, Weigel HM, Ten Kate RW, Mulder JW, Frissen PH, van Leeuwen R, Reiss P, Schuitemaker H, de Wolf F, Lange JM: Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication study. Lancet. 1998, 352: 185-190. 10.1016/S0140-6736(98)06193-5.CrossRefPubMed
17.
go back to reference Havlir DV, Marschner IC, Hirsch MS, Collier AC, Tebas P, Bassett RL, Ioannidis JP, Holohan MK, Leavitt R, Coone G, Richman DD: Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N Engl J Med. 1998, 339: 1261-1268. 10.1056/NEJM199810293391801.CrossRefPubMed Havlir DV, Marschner IC, Hirsch MS, Collier AC, Tebas P, Bassett RL, Ioannidis JP, Holohan MK, Leavitt R, Coone G, Richman DD: Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N Engl J Med. 1998, 339: 1261-1268. 10.1056/NEJM199810293391801.CrossRefPubMed
18.
go back to reference Pialoux G, Raffi F, Brun-Vezinet F, Meiffrédy V, Flandre P, Gastaut J, Dellamonica P, Yeni P, Delfraissy J, Aboulker J: A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team. N Engl J Med. 1998, 339: 1269-1276. 10.1056/NEJM199810293391802.CrossRefPubMed Pialoux G, Raffi F, Brun-Vezinet F, Meiffrédy V, Flandre P, Gastaut J, Dellamonica P, Yeni P, Delfraissy J, Aboulker J: A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team. N Engl J Med. 1998, 339: 1269-1276. 10.1056/NEJM199810293391802.CrossRefPubMed
19.
go back to reference Descamps D, Flandre P, Calvez V, Peytavin G, Meiffrédy V, Collin G, Delaugerre C, Robert-Delmas S, Bazin B, Aboulker JP, Pialoux G, Raffi F, Brun-Vézinet F: Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. JAMA. 2000, 283: 205-211. 10.1001/jama.283.2.205.CrossRefPubMed Descamps D, Flandre P, Calvez V, Peytavin G, Meiffrédy V, Collin G, Delaugerre C, Robert-Delmas S, Bazin B, Aboulker JP, Pialoux G, Raffi F, Brun-Vézinet F: Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. JAMA. 2000, 283: 205-211. 10.1001/jama.283.2.205.CrossRefPubMed
20.
go back to reference Curlin M, Iyer S, Mittler J: Optimal timing and duration of induction therapy for HIV-1 infection. PLoS Comput Biol. 2007, 3 (7): e133-10.1371/journal.pcbi.0030133.CrossRefPubMedPubMedCentral Curlin M, Iyer S, Mittler J: Optimal timing and duration of induction therapy for HIV-1 infection. PLoS Comput Biol. 2007, 3 (7): e133-10.1371/journal.pcbi.0030133.CrossRefPubMedPubMedCentral
21.
go back to reference Havlir D, Hellmann NS, Petropoulos CJ, Whitcomb JM, Collier AC, Hirsch MS, Tebas P, Sommadossi JP, Richman DD: Drug Susceptibility in HIV infection after Viral Rebound in Patients Recieving Indinavir-Containing Regimens. JAMA. 2000, 283: 299-234. 10.1001/jama.283.2.229.CrossRef Havlir D, Hellmann NS, Petropoulos CJ, Whitcomb JM, Collier AC, Hirsch MS, Tebas P, Sommadossi JP, Richman DD: Drug Susceptibility in HIV infection after Viral Rebound in Patients Recieving Indinavir-Containing Regimens. JAMA. 2000, 283: 299-234. 10.1001/jama.283.2.229.CrossRef
22.
go back to reference Pai N, Lawrence J, Reingold AL, Tulsky J: Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults. Cochrane Database of Systematic Reviews. 2006, 3: CD006148-PubMed Pai N, Lawrence J, Reingold AL, Tulsky J: Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults. Cochrane Database of Systematic Reviews. 2006, 3: CD006148-PubMed
23.
go back to reference Chesney MA, Morin M, Sherr L: Adherence to HIV combination therapy. Social Science & Medicine. 2000, 50: 1599-1605. 10.1016/S0277-9536(99)00468-2.CrossRef Chesney MA, Morin M, Sherr L: Adherence to HIV combination therapy. Social Science & Medicine. 2000, 50: 1599-1605. 10.1016/S0277-9536(99)00468-2.CrossRef
24.
go back to reference Curlin ME, Wilkin T, Mittler J: Induction-maintenance therapy for HIV-1 infection. Future HIV Therapy. 2008, 2: 175-185. 10.2217/17469600.2.2.175.CrossRef Curlin ME, Wilkin T, Mittler J: Induction-maintenance therapy for HIV-1 infection. Future HIV Therapy. 2008, 2: 175-185. 10.2217/17469600.2.2.175.CrossRef
25.
go back to reference Cohen CJ, Colson AE, Sheble-Hall AG, McLaughlin KA, Morse GD: Pilot Study of a Novel Short-Cycle Antiretroviral Treatment Interruption Strategy: 48-Week Results of the Five-Days-On, Two-Days-Off (FOTO) Study. HIV Clin Trials. 2007, 8: 19-23. 10.1310/hct0801-19.CrossRefPubMed Cohen CJ, Colson AE, Sheble-Hall AG, McLaughlin KA, Morse GD: Pilot Study of a Novel Short-Cycle Antiretroviral Treatment Interruption Strategy: 48-Week Results of the Five-Days-On, Two-Days-Off (FOTO) Study. HIV Clin Trials. 2007, 8: 19-23. 10.1310/hct0801-19.CrossRefPubMed
26.
go back to reference Smith RJ, Wahl LM: Drug resistance in an immunological model of HIV-1 infection with impulsive drug effects. Bull Math Biol. 2005, 67: 783-813. 10.1016/j.bulm.2004.10.004.CrossRefPubMed Smith RJ, Wahl LM: Drug resistance in an immunological model of HIV-1 infection with impulsive drug effects. Bull Math Biol. 2005, 67: 783-813. 10.1016/j.bulm.2004.10.004.CrossRefPubMed
27.
go back to reference Smith RJ, Aggarwala BD: Can the viral reservoir of latently infected CD4+ T cells be eradicated with antiretroviral drugs?. J Math Biol. 2009, 59: 697-715. 10.1007/s00285-008-0245-4.CrossRefPubMed Smith RJ, Aggarwala BD: Can the viral reservoir of latently infected CD4+ T cells be eradicated with antiretroviral drugs?. J Math Biol. 2009, 59: 697-715. 10.1007/s00285-008-0245-4.CrossRefPubMed
28.
go back to reference Bainov DD, Simeonov PS: Systems with Impulsive Effect. 1989, Chichester: Ellis Horwood Ltd Bainov DD, Simeonov PS: Systems with Impulsive Effect. 1989, Chichester: Ellis Horwood Ltd
29.
go back to reference Bainov DD, Simeonov PS: Impulsive differential equations: periodic solutions and applications. 1993, Burnt Mill: Longman Scientific and Technical Bainov DD, Simeonov PS: Impulsive differential equations: periodic solutions and applications. 1993, Burnt Mill: Longman Scientific and Technical
30.
go back to reference Bainov DD, Simeonov PS: Impulsive Differential Equations: Asymptotic Properties of the Solutions. 1995, Singapore: World Scientific Bainov DD, Simeonov PS: Impulsive Differential Equations: Asymptotic Properties of the Solutions. 1995, Singapore: World Scientific
31.
go back to reference Lakshmikantham V, Bainov DD, Simeonov PS: Systems with Impulsive Effect. 1989, Singapore: World Scientific Lakshmikantham V, Bainov DD, Simeonov PS: Systems with Impulsive Effect. 1989, Singapore: World Scientific
32.
go back to reference Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD: CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006, 355 (22): 2283-2296. 10.1056/NEJMoa062360.CrossRef Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD: CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006, 355 (22): 2283-2296. 10.1056/NEJMoa062360.CrossRef
33.
go back to reference DART Trial Team: Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts < 200 cells/microl. AIDS. 2008, 22 (2): 237-247. 10.1097/QAD.0b013e3282f2d760.CrossRef DART Trial Team: Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts < 200 cells/microl. AIDS. 2008, 22 (2): 237-247. 10.1097/QAD.0b013e3282f2d760.CrossRef
34.
go back to reference Holkmann Olsen C, Mocroft A, Kirk O, Vella S, Blaxhult A, Clumeck N, Fisher M, Katlama C, Phillips A, Lundgren J: Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. HIV Med. 2007, 8: 96-104. 10.1111/j.1468-1293.2007.00436.x.CrossRefPubMed Holkmann Olsen C, Mocroft A, Kirk O, Vella S, Blaxhult A, Clumeck N, Fisher M, Katlama C, Phillips A, Lundgren J: Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. HIV Med. 2007, 8: 96-104. 10.1111/j.1468-1293.2007.00436.x.CrossRefPubMed
35.
go back to reference Li X, Margolick J, Conover C, Badri S, Riddler SA, Witt MD, Jacobson LP: Interruption and Discontinuation of Highly Active Antiretroviral Therapy in the Multicenter AIDS Cohort Study. JAIDS. 2005, 38: 320-328.PubMed Li X, Margolick J, Conover C, Badri S, Riddler SA, Witt MD, Jacobson LP: Interruption and Discontinuation of Highly Active Antiretroviral Therapy in the Multicenter AIDS Cohort Study. JAIDS. 2005, 38: 320-328.PubMed
36.
go back to reference Papasavvas E, Kostman JR, Mounzer K, Grant RM, Gross R, Gallo C, Azzoni L, Foulkes A, Thiel B, Pistilli M, Mackiewicz A, Shull J, Montaner LJ: Randomized, Controlled Trial of Therapy Interruption in Chronic HIV-1 Infection. PLoS Medicine. 2004, 1 (3): e64-10.1371/journal.pmed.0010064.CrossRefPubMedPubMedCentral Papasavvas E, Kostman JR, Mounzer K, Grant RM, Gross R, Gallo C, Azzoni L, Foulkes A, Thiel B, Pistilli M, Mackiewicz A, Shull J, Montaner LJ: Randomized, Controlled Trial of Therapy Interruption in Chronic HIV-1 Infection. PLoS Medicine. 2004, 1 (3): e64-10.1371/journal.pmed.0010064.CrossRefPubMedPubMedCentral
38.
go back to reference Ait-Khaled M, Stone C, Amphlett G, Clotet B, Staszewski S, Katlama C, Tisdale M, CNA3002 International Study Team: M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine. AIDS. 2002, 16: 1686-1689. 10.1097/00002030-200208160-00017.CrossRefPubMed Ait-Khaled M, Stone C, Amphlett G, Clotet B, Staszewski S, Katlama C, Tisdale M, CNA3002 International Study Team: M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine. AIDS. 2002, 16: 1686-1689. 10.1097/00002030-200208160-00017.CrossRefPubMed
39.
go back to reference Smith RJ, Schwartz EJ: Predicting the potential impact of a cytotoxic T-lymphocyte HIV vaccine: how often should you vaccinate and how strong should the vaccine be?. Math Biosci. 2008, 212: 180-187. 10.1016/j.mbs.2008.02.001.CrossRefPubMed Smith RJ, Schwartz EJ: Predicting the potential impact of a cytotoxic T-lymphocyte HIV vaccine: how often should you vaccinate and how strong should the vaccine be?. Math Biosci. 2008, 212: 180-187. 10.1016/j.mbs.2008.02.001.CrossRefPubMed
40.
go back to reference Chun TW, Nickle DC, Justement JS, Meyers JH, Roby G, Hallahan CW, Kottilil S, Moir S, Mican JM, Mullins JI, Ward DJ, Kovacs JA, Mannon PJ, Fauci AS: Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis. 2008, 197: 714-720. 10.1086/527324.CrossRefPubMed Chun TW, Nickle DC, Justement JS, Meyers JH, Roby G, Hallahan CW, Kottilil S, Moir S, Mican JM, Mullins JI, Ward DJ, Kovacs JA, Mannon PJ, Fauci AS: Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis. 2008, 197: 714-720. 10.1086/527324.CrossRefPubMed
41.
go back to reference Scott L, Perry C: Delavirdine - A review of its use in HIV infection. Drugs. 2000, 60: 1411-1444. 10.2165/00003495-200060060-00013.CrossRefPubMed Scott L, Perry C: Delavirdine - A review of its use in HIV infection. Drugs. 2000, 60: 1411-1444. 10.2165/00003495-200060060-00013.CrossRefPubMed
42.
go back to reference Perry C, Noble S: Didanosine - An update review of its use in HIV infection. Drugs. 1999, 58: 1099-1135. 10.2165/00003495-199958060-00009.CrossRefPubMed Perry C, Noble S: Didanosine - An update review of its use in HIV infection. Drugs. 1999, 58: 1099-1135. 10.2165/00003495-199958060-00009.CrossRefPubMed
43.
go back to reference Bhana N, Ormrod D, Perry C, Figgitt D: Zidovudine - A review of its use in management of vertically-aquired pediatric HIV infection. Drugs. 2002, 4: 515-553. Bhana N, Ormrod D, Perry C, Figgitt D: Zidovudine - A review of its use in management of vertically-aquired pediatric HIV infection. Drugs. 2002, 4: 515-553.
44.
go back to reference Hervey P, Perry C: Abacavir - A review of its clinical potential in patients with HIV infection. Drugs. 2000, 60: 447-479. 10.2165/00003495-200060020-00015.CrossRefPubMed Hervey P, Perry C: Abacavir - A review of its clinical potential in patients with HIV infection. Drugs. 2000, 60: 447-479. 10.2165/00003495-200060020-00015.CrossRefPubMed
45.
go back to reference Frampton J, Perry C: Emtricitabine - A review of its use in management of HIV infection. Drugs. 2006, 65: 1427-1448. 10.2165/00003495-200565100-00008.CrossRef Frampton J, Perry C: Emtricitabine - A review of its use in management of HIV infection. Drugs. 2006, 65: 1427-1448. 10.2165/00003495-200565100-00008.CrossRef
46.
go back to reference Moore KHP, Barrett JE, Shaw S, Pakes GE, Churchus R, Kapoor A, Barry MG, D B: The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS. 1999, 13: 2239-2250. 10.1097/00002030-199911120-00006.CrossRefPubMed Moore KHP, Barrett JE, Shaw S, Pakes GE, Churchus R, Kapoor A, Barry MG, D B: The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS. 1999, 13: 2239-2250. 10.1097/00002030-199911120-00006.CrossRefPubMed
47.
go back to reference Fletcher C, Brundage R, Remmel R, Page L, Weller D, Calles N, Simon C, Kline M: Pharmacologic characteristics of indinivir, didanosine, stavudine, in human immunodeficiency virus-infected children receiving combination therapy. Antimicrobial Agents and Chemotherapy. 2000, 44: 1029-1034. 10.1128/AAC.44.4.1029-1034.2000.CrossRefPubMedPubMedCentral Fletcher C, Brundage R, Remmel R, Page L, Weller D, Calles N, Simon C, Kline M: Pharmacologic characteristics of indinivir, didanosine, stavudine, in human immunodeficiency virus-infected children receiving combination therapy. Antimicrobial Agents and Chemotherapy. 2000, 44: 1029-1034. 10.1128/AAC.44.4.1029-1034.2000.CrossRefPubMedPubMedCentral
48.
go back to reference Hawkins T, Veikley W, St Claire R, Guyer B, Clark N, Kearney B: Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J Acquir Defic Syndr. 2001, 39: 406-411. 10.1097/01.qai.0000167155.44980.e8.CrossRef Hawkins T, Veikley W, St Claire R, Guyer B, Clark N, Kearney B: Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J Acquir Defic Syndr. 2001, 39: 406-411. 10.1097/01.qai.0000167155.44980.e8.CrossRef
Metadata
Title
Modelling imperfect adherence to HIV induction therapy
Authors
Rachelle E Miron
Robert J Smith
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2010
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-10-6

Other articles of this Issue 1/2010

BMC Infectious Diseases 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.